Skip to main content
. Author manuscript; available in PMC: 2021 Aug 15.
Published in final edited form as: Eur J Pharmacol. 2020 May 31;881:173233. doi: 10.1016/j.ejphar.2020.173233

Fig. 5. NAC treatment resulted in sustained elevation of circulating EPCs population in mice with chronic limb ischemia.

Fig. 5.

Blood cells were collected for EPCs analysis after limb ischemia at day 3 and 21. Mice without limb ischemia were used as control. Flow cytometry analysis demonstrated that circulating Sca-1+/Flk-1+ cell population was initially increased significantly at day 3, then returned to baseline level at day 21 (B and D). CD34+/Flk-1+ cell population in blood was at low level at day 3, and only slightly increased at day 21 (A). The levels of all circulating EPCs were significantly increased by 2-3 folds at day 21 in mice treated with NAC compared to the control mice (A-D). On the other hand, NAC treatment resulted in a sustained elevation of circulating EPCs population (CD34+/Flk-1+, Sca-1+/Flk-1+, c-Kit+/CD31+ and CD34+/CD133+) in mice at day 21 of limb ischemia compared to the control, while leading to a significant reduction in the number of circulating Sca-1+/Flk-1+ cells and CD34+/CD133+ cells in mice at day 3 after limb ischemia. *Day 3 or 21 vs Ctrl, P <0.05, n≥8; $Day21 vs 3, P <0.05, n≥8; #ctrl vs NAC, P <0.05, n≥8.